Welcome to LookChem.com Sign In|Join Free
  • or
MK-1496, also known as guadecitabine, is a next-generation hypomethylating agent that has shown potential as a treatment for various types of cancer. It is a dinucleotide of decitabine and deoxyguanosine that forms within cells after oral or intravenous administration. MK-1496 works by incorporating into DNA and inhibiting DNA methyltransferase, leading to the demethylation of DNA and reactivation of tumor suppressor genes. Preclinical studies have demonstrated its antileukemic activity, and clinical trials are exploring its efficacy in treating myelodysplastic syndromes, acute myeloid leukemia, and other solid tumors. MK-1496 has the potential to provide a new therapeutic option for patients with different cancer types.

1037254-47-9

Post Buying Request

1037254-47-9 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1037254-47-9 Usage

Uses

Used in Oncology:
MK-1496 is used as a hypomethylating agent for the treatment of various types of cancer. It is particularly effective in targeting myelodysplastic syndromes, acute myeloid leukemia, and other solid tumors. The drug works by incorporating into DNA, inhibiting DNA methyltransferase, and inducing demethylation of DNA, which results in the reactivation of tumor suppressor genes and suppression of cancer growth.
Used in Preclinical Research:
MK-1496 is used as a research tool in preclinical studies to evaluate its antileukemic activity and explore its potential in treating different types of cancer. These studies provide valuable insights into the drug's mechanism of action, efficacy, and safety profile, paving the way for clinical trials and future cancer treatments.
Used in Clinical Trials:
MK-1496 is used as an investigational drug in clinical trials to assess its safety, tolerability, and efficacy in treating patients with myelodysplastic syndromes, acute myeloid leukemia, and other solid tumors. These trials are crucial for determining the optimal dosing regimens, identifying potential side effects, and establishing the drug's therapeutic potential in various cancer types.

Check Digit Verification of cas no

The CAS Registry Mumber 1037254-47-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,3,7,2,5 and 4 respectively; the second part has 2 digits, 4 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1037254-47:
(9*1)+(8*0)+(7*3)+(6*7)+(5*2)+(4*5)+(3*4)+(2*4)+(1*7)=129
129 % 10 = 9
So 1037254-47-9 is a valid CAS Registry Number.

1037254-47-9SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 15, 2017

Revision Date: Aug 15, 2017

1.Identification

1.1 GHS Product identifier

Product name 1-[4-(1-aminoethyl)phenyl]-2-(tert-butylamino)ethanol

1.2 Other means of identification

Product number -
Other names -

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:1037254-47-9 SDS

1037254-47-9Relevant academic research and scientific papers

NOVEL AMINOPYRIMIDINE DERIVATIVES AS PLK1 INHIBITORS

-

Page/Page column 66, (2008/12/07)

The present invention relates to a compound represented by Formula [I]: or a pharmaceutically acceptable salt or ester thereof, wherein R1 and R2, which may be the same or different, are each a hydrogen atom, a halogen atom, a lower

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 1037254-47-9